10 Things Worth Pay...
Health Care: Drugs
CytRx Corporation (CYTR: NASDAQ)
$3.58 -0.30 | -7.73%
06/04/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 250.00K | 100.00K | 9.50M | 6.27M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 250.00K | 100.00K | 9.50M | 6.27M |
| Selling, General, and Administrative Expenses | 7.32M | 8.24M | 9.13M | 10.93M |
| Research & Development | 15.49M | 8.51M | 7.54M | 10.47M |
| Operating Income before D & A (EBITDA) | -22.56M | -16.64M | -7.17M | -15.13M |
| Depreciation & Amortization | 95.52K | 107.67K | 475.32K | 624.98K |
| Interest Income | 207.22K | 303.59K | 349.49K | 1.20M |
| Other Income - Net | 8.12M | 1.03M | 1.98M | 219.49K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -14.33M | 408.46K | -5.32M | -26.17M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Pre-Tax Income | -14.33M | 408.46K | -5.32M | -26.17M |
| Income Taxes | 98.00K | 0.00 | -519.16K | 873.00K |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -14.42M | 408.46K | -4.80M | -27.05M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -14.42M | 408.46K | -4.80M | -27.05M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -14.42M | 408.46K | -4.80M | -27.05M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-14.42M | 408.46K | -4.80M | -19.03M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -14.42M | 408.46K | -4.80M | -27.80M |
| Basic EPS from Continuing Ops. | -0.77 | 0.00 | -0.35 | -2.10 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.77 | 0.00 | -0.35 | -2.10 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.77 | 0.00 | -0.35 | -2.10 |
| Basic Normalized Net Income/Share | -0.77 | n.a. | -0.35 | -1.48 |
| EPS fr Continuing Ops. | -0.77 | 0.00 | -0.35 | -2.10 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.77 | 0.00 | -0.35 | -2.10 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.77 | 0.00 | -0.35 | -2.10 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.77 | n.a. | -0.35 | -1.48 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CYTR
- Portfolio NameUser Type
- Uservlady 1
- Contributor5 Stocks Under-$10 Setting ...
- UserHope For The Best
- Userrick epple
- ContributorBarron's Research Reports 1...
- UserNat's
- UserHi Potential
- Usernewintrade Portfolio 1
- Usersteveandvickie Portfolio 1
- Useractive-jrd
Latest CYTR Headlines from TheStreet
- 5 Stocks Under $10 With Big Upside Potential 11.18.11 | 06:11 am
- SeaChange, Tenet: Early Volume Plays 12.03.09 | 08:12 am
- CytRx: FDA Lifts 2-year Hold On Arimoclomol Tests 12.02.09 | 09:12 am
- Correction: CytRx FDA Letter 09.09.09 | 04:09 pm
- CytRx Expects To File FDA Response In 4Q 09.08.09 | 10:09 am
- CytRx Rises On Preclinical Data For Stroke Drug 08.24.09 | 01:08 pm
- Movers Roundup: Massey Energy, MannKind 06.08.09 | 02:06 pm
- CytRx Rises On Analyst's 'Outperform' Rating 06.08.09 | 01:06 pm
- Biotech Notebook: Nastech, Amgen, PDL BioPharma 11.15.07 | 04:11 pm
- Wednesday's Health Winners & Losers 11.14.07 | 03:11 pm
Press Releases for CYTR
- CytRx To Hold Conference Call Today At 10:00 A.m. Eastern Time To Discuss Favorable Results From INNO-206 Clinical Trial In Soft Tissue Sarcoma - Business Wire 06.04.12 | 08:06 am
- CytRx Announces Favorable Results From Phase 1b/2 Clinical Trial With INNO-206 - Business Wire 06.03.12 | 09:06 am
- CytRx Regains NASDAQ Compliance - Business Wire 06.01.12 | 08:06 am
- CytRx Announces The Publication Of INNO-206 Findings In Multiple Myeloma In Clinical Cancer Research - Business Wire 05.29.12 | 08:05 am
- CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer - Business Wire 04.26.12 | 08:04 am
- CytRx Receives NASDAQ Extension - Business Wire 04.23.12 | 08:04 am
- CytRx Announces Issuance Of Key U.S. Patent Covering INNO-206 Linker Technology - Business Wire 04.12.12 | 08:04 am
- CytRx’s INNO-206 To Be Featured In Two Presentations At The American Association For Cancer Research (AACR) 2012 Annual Meeting - Business Wire 03.27.12 | 08:03 am
- CytRx Reports 2011 Financial Results - Business Wire 03.13.12 | 08:03 am
- CytRx To Present At The Roth Capital Partners Annual OC Growth Stock Conference - Business Wire 03.05.12 | 08:03 am
Partner Headlines for CYTR
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
- Why CytRx Corporation Is Still A Big Biotech 'If' Play - Seeking Alpha 12.14.11 | 09:12 am
- CytRx Is Poised For Growth - Analyst Blog - Zacks 08.13.11 | 12:08 am
- CytRx Reports 2Q 2011 Results - Analyst Blog - Zacks 08.12.11 | 06:08 pm
- As the Market Dips, It's Time to Look for Biotech Sector Deals - Seeking Alpha 06.12.11 | 09:06 am
- CytRx Completes Sale of Molecular Chaperone Assets - Analyst Blog - Zacks 05.17.11 | 09:05 am
- Company News for April 29, 2011 - Corporate Summary - Zacks 04.29.11 | 10:04 am
- Stocks Mixed at Session's Half on Slowing Q1 Economy; Crude Futures Advance - NASDAQ 04.28.11 | 04:04 pm
- Mid-Day Update: Stocks Mixed as GDP Data Weighs; Jobless Claims Rise - NASDAQ 04.28.11 | 04:04 pm
- China Analyst: 10 Pharma Stocks With Highest Growth Potential - Seeking Alpha 10.08.10 | 06:10 am
